United Therapeutics Corp (UTHR)
Health Care ยท Pharmaceutical Preparations
United Therapeutics Corp (UTHR) is listed on Nasdaq, where its shares have traded since June 17, 1999. SentiSense covers United Therapeutics Corp in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Martine Rothblatt is its chief executive officer. The company reports 1,400 employees, and its corporate website is www.unither.com.
About United Therapeutics Corp
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 862 institutions reported holding UTHR, with 41.4 million shares worth $22.5 billion in aggregate. The largest reported holders were BlackRock, Vanguard and Avoro Capital Advisors. Of the 5 largest reported holders, 2 added shares and 3 reduced their positions during the quarter.
More on UTHR
- UTHR sentiment: whether news and social coverage of United Therapeutics Corp leans bullish or bearish, and the stories driving it.
- UTHR ownership: all 862 reporting institutions, plus insider and congressional trades.
- UTHR financials: revenue, net income, operating margin and free cash flow by quarter and year.
Frequently asked questions
What does United Therapeutics Corp do?
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs.
What sector is UTHR in?
SentiSense classifies United Therapeutics Corp in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does UTHR stock trade?
United Therapeutics Corp (UTHR) is listed on Nasdaq, where its shares have traded since June 17, 1999.
Who is the CEO of United Therapeutics Corp?
Martine Rothblatt is the chief executive officer of United Therapeutics Corp.